ClinicalTrials.Veeva

Menu

Impact of APP-assisted Patient Management on the Quality Control of Blood Purification Therapy

Y

Yunfeng Xia

Status

Enrolling

Conditions

Maintenance Hemodialysis
End Stage Renal Disease (ESRD)

Treatments

Behavioral: APP-based management

Study type

Interventional

Funder types

Other

Identifiers

NCT07291154
1st ChongqingMedicalUniversity

Details and patient eligibility

About

Many maintenance hemodialysis (MHD) patients develop negative outlooks due to their illnesses and complications, making their quality of life and prognosis a clinical concern. Effective life management and treatment cooperation are crucial to improving dialysis quality and patient outcomes. This trial aims to evaluate whether management through the "Yueya" mini-program and WeChat can provide personalized guidance such as health education, diet, exercise, medication supervision, and condition monitoring to enhance treatment compliance, quality of life, strengthen quality control in the hemodialysis unit, and improve patient prognosis.

Patients will be divided into a group receiving support via the "Yueya" mini-program and WeChat, and a control group receiving routine care. Clinical and laboratory indicators, cardiovascular events, death, hospitalization, quality of life, and compliance will be recorded and compared between groups to assess the impact of APP-assisted patient management on the quality of MHD blood purification therapy and the prognosis of MHD patients.

Full description

Affected by their own diseases and various complications, many maintenance hemodialysis (MHD) patients have a negative and pessimistic attitude toward life. Their quality of life and prognosis have always been a concern for clinicians. Therefore, how to adjust and manage the lives of these patients, enable them to actively cooperate with various treatment methods, maximize the quality of blood purification therapy, and improve their quality of life and prognosis has become an extremely important research topic.

Enrollment

392 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with stage 5 chronic kidney disease, who have received maintenance hemodialysis for more than 3 months, are aged between 18 and 75 years old, and have regular dialysis three times a week.
  • Patients with relatively stable condition, who are able to take care of themselves and willing to cooperate with the study.
  • Patients who can understand and proficiently use WeChat and the "Yueya" mini - program used in this study.

Exclusion criteria

  • Patients with communication barriers or other conditions that prevent them from cooperating with the study.
  • Patients who have a history of acute myocardial infarction, cerebral infarction or intracerebral hemorrhage in the past six months.
  • Patients who are not willing to actively cooperate with the study.
  • Patients with severe liver cirrhosis, active tuberculosis and AIDS.

Trial design

Primary purpose

Health Services Research

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

392 participants in 2 patient groups

APP management group
Experimental group
Description:
For the APP management group, according to the specific conditions of patients such as age, gender, primary disease and complications, the "Yueya" mini-program and WeChat will be used to provide individualized and all-weather guidance for dialysis patients in their daily lives, including health knowledge education, diet and exercise guidance, medication supervision, condition monitoring and real-time feedback.
Treatment:
Behavioral: APP-based management
Non-APP management group
No Intervention group
Description:
For the non-APP management group, the APP mini-program will not be used to guide patients' daily lives, and only the previous routine management methods will be adopted.

Trial contacts and locations

1

Loading...

Central trial contact

Yunfeng Xia Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems